Some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have been better in practice compared with clinical trials, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai.
It’s not uncommon for real-world results and outcomes for a treatment to be worse than those seen in clinical trials, which are more tightly controlled and have strict inclusion criteria. However, some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have been better in practice, said Emma Guttman-Yassky, MD, PhD, FAAD, the Waldman Professor and System Chair of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai, the director of the Center for Excellence in Eczema and the Occupational Dermatitis Clinic, and director of the Laboratory for Inflammatory Skin Diseases.
The first biologic to treat atopic dermatitis was approved in 2017 and the first oral JAK inhibitors were approved in January 2022.
Transcript
With a couple of years of data of real-world use for biologics and JAK inhibitors to treat atopic dermatitis, what have you seen regarding real-world adherence and efficacy compared with what was seen in the clinical trials?
So yes, for some, actually, we see better results in practice. One such drug is tralokinumab, which targets IL-13. I have to say, I have a very good experience in real life. Part of it is that in the clinical trial, they had a very long washout from topical steroids, and that may have resulted in less good data. But we have good experience now in the real life and also less conjunctivitis, so I think that is good.
Also, I have very good experience now with the JAK inhibitors, both upadacitinib, and also very good experience with abrocitinib from Pfizer—maybe a little bit better than what we've seen in clinical studies. We need to remember their clinical study was 12 weeks, whereas upadacitinib was 16 weeks, and that may make some difference. But we see very good results in real life.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Review: One-Shot Etranacogene Dezaparvovec Represents Game-Changing Gene Therapy for Hemophilia B
May 3rd 2024More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current and potentially many future genomic medicines for a range of diseases.
Read More